NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free FBIO Stock Alerts $1.87 +0.03 (+1.63%) (As of 05/24/2024 04:00 PM ET) Add Compare Share Share Today's Range$1.82▼$1.9050-Day Range$1.67▼$2.1752-Week Range$1.24▼$10.65Volume69,100 shsAverage Volume342,733 shsMarket Capitalization$37.25 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fortress Biotech alerts: Email Address Fortress Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,504.3% Upside$30.00 Price TargetShort InterestBearish12.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 7 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthGrowingFrom ($6.57) to ($5.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.98 out of 5 starsMedical Sector365th out of 921 stocksPharmaceutical Preparations Industry171st out of 431 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Fortress Biotech's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.69% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 3.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 3.1 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search Interest12 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows6 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $17,600.00 in company stock and sold $18,900.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders33.40% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fortress Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($6.57) to ($5.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 18.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fortress Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Fortress Biotech Stock (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesMay 21, 2024 | insidertrades.comInsider Buying: Fortress Biotech, Inc. (NASDAQ:FBIO) CEO Buys 10,000 Shares of StockMay 24 at 3:12 AM | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Stock Rating Lowered by StockNews.comMay 21, 2024 | americanbankingnews.comFortress Biotech, Inc. (NASDAQ:FBIO) Director Dov Klein Sells 10,000 Shares of StockMay 21, 2024 | americanbankingnews.comFortress Biotech, Inc. (NASDAQ:FBIO) CEO Lindsay A. Md Rosenwald Buys 10,000 Shares of StockMay 19, 2024 | americanbankingnews.comRoth Mkm Reaffirms Buy Rating for Fortress Biotech (NASDAQ:FBIO)May 18, 2024 | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Rating Increased to Hold at StockNews.comMay 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)May 16, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 16, 2024 | finance.yahoo.comFortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseMay 16, 2024 | finance.yahoo.comAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)May 16, 2024 | globenewswire.comFortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseMay 15, 2024 | globenewswire.comFortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 15, 2024 | globenewswire.comJourney Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseMay 14, 2024 | globenewswire.comFortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationMay 13, 2024 | globenewswire.comJourney Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 13, 2024 | globenewswire.comCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 10, 2024 | globenewswire.comCheckpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 7, 2024 | globenewswire.comJourney Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024May 1, 2024 | globenewswire.comJourney Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerApril 25, 2024 | globenewswire.comJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024April 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024March 29, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | globenewswire.comFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 28, 2024 | msn.comMustang Bio stock climbs 9% amid drug development updateSee More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees187Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$75.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,504.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.0982) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,640,000.00 Net Margins-69.13% Pretax Margin-161.56% Return on Equity-770.86% Return on Assets-35.47% Debt Debt-to-Equity Ratio38.42 Current Ratio1.33 Quick Ratio1.21 Sales & Book Value Annual Sales$84.51 million Price / Sales0.44 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book18.70Miscellaneous Outstanding Shares19,920,000Free Float13,264,000Market Cap$37.25 million OptionableOptionable Beta1.56 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey CompetitorsChimerixNASDAQ:CMRXscPharmaceuticalsNASDAQ:SCPHRegulus TherapeuticsNASDAQ:RGLSSangamo TherapeuticsNASDAQ:SGMOVerastemNASDAQ:VSTMView All CompetitorsInsiders & InstitutionsDov KleinSold 10,000 sharesTotal: $18,900.00 ($1.89/share)Virtu Financial LLCBought 15,310 shares on 5/20/2024Ownership: 0.077%Lindsay A Md RosenwaldBought 10,000 shares on 5/16/2024Total: $17,600.00 ($1.76/share)Acadian Asset Management LLCBought 161,870 shares on 5/10/2024Ownership: 1.518%Shikiar Asset Management Inc.Bought 40,000 shares on 4/22/2024Ownership: 1.160%View All Insider TransactionsView All Institutional Transactions FBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price target for 2024? 3 Wall Street research analysts have issued 1-year price objectives for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they predict the company's share price to reach $30.00 in the next year. This suggests a possible upside of 1,504.3% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2024? Fortress Biotech's stock was trading at $3.01 at the beginning of the year. Since then, FBIO stock has decreased by 37.9% and is now trading at $1.87. View the best growth stocks for 2024 here. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) posted its quarterly earnings data on Thursday, March, 28th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $19.95 million during the quarter, compared to analysts' expectations of $14.46 million. Fortress Biotech had a negative trailing twelve-month return on equity of 770.86% and a negative net margin of 69.13%. When did Fortress Biotech's stock split? Shares of Fortress Biotech reverse split on Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (1.52%), Shikiar Asset Management Inc. (1.16%), PFG Investments LLC (0.08%) and Virtu Financial LLC (0.08%). Insiders that own company stock include Dov Klein, Lindsay A Md Rosenwald and Michael S Weiss. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBIO) was last updated on 5/27/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyJust $9 for a Year of Winning Market InsightsBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.